Other Investments Ideas
VolatilityHypeValuationAnalyst ConsensusFinancial LeverageOdds of DistressMacroaxis Advice
XLRN
Not Suitable
ADAP
Not Suitable
ADRO
Not Available
ADXS
Not Suitable
AGEN
Not Suitable
ANGO
Not Suitable
ARGX
Not Suitable
ARRY
Not Suitable
ATRA
Not Suitable
ANTX
Not Available
Not Suitable
BGNE
Not Suitable
BLCM
Not Suitable
BYSI
Not Suitable
BPMC
Not Suitable
CLLS
Not Suitable
CLDX
Not Suitable
CCXI
Not Suitable
CRVS
Not Suitable
CRIS
Not Suitable
CTMX
Not Suitable
DCPH
Not Suitable
EGRX
Not Suitable
EPZM
Not Suitable
ERYP
Not Suitable
FGEN
Not Suitable
GTHX
Not Suitable
GERN
Not Suitable
HALO
Not Suitable
HRTX
Not Suitable
HCM
Not Suitable
RXDX
Not Suitable
IMMU
Not Suitable
INO
Not Suitable
IOVA
Not Suitable
JNCE
Not Suitable
KDMN
Not Suitable
KPTI
Not Suitable
LOXO
Not Suitable
MGNX
Not Suitable
MACK
Not Suitable
MRSN
Not Suitable
MESO
Not Suitable
MNTA
Not Suitable
NLNK
Not Available
NVCR
Not Suitable
NCNA
Not Available
OMED
Not Suitable
PGNX
Not Suitable
PTCT
Not Suitable
PBYI
Not Suitable
RIGL
Not Suitable
SPPI
Not Suitable
SYRS
Not Suitable
TGTX
Not Suitable
XBIT
Not Available
ZLAB
Not Available
Not Available
ZIOP
Not Available
REGN
CELG
BDX
This investing idea covers USA markets and includes biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. To change this theme please use the panel above. To change the current investment horizon use the link on the top of the page, or select one of many other different investing ideas from the investing ideas screen. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools
Macroaxis provides instant equity rating and digital advice for all thematic ideas, such as Cancer Fighters, based on a combination of real-time fundamental analysis and risk-adjusted market performance. The results are broken down into six categories that are weighted to derive a horizon based recommendation. Every one of these categories can also be evaluated separately.